Treating Acute Leukemias
in the Asia-Pacific Region

A Worldwide Collaboration to Define and Refine the Most Effective Treatments in Leukemias

Overview

In recent years, progress in the understanding of acute leukemias has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Leukemia Academy to help physicians who treat acute leukemias bridge the gap between innovation and implementation for patient care.

Date and Location

December 5–6, 2022, Webinar

Meeting Content

View the slides and watch the video of Day 1
Virtual Plenary Sessions

View the slides and watch the video of Day 2
Virtual Breakout: Adult Leukemia Patients

View the slides and watch the video of Day 2
Virtual Breakout: Pediatric ALL Patients

Chair

Elias Jabbour

Elias Jabbour, MD

MD Anderson Cancer Center,
USA

Faculty

Stephanie Dixon

Stephanie Dixon, MD, MPH

St. Jude Children’s Research Hospital, USA

Shaun Fleming

Shaun Fleming, MBBS(Hons), FRACP, FRCPA

Melbourne Haematology, Richmond, VIC, Australia

Hagop Kantarjian

Hagop Kantarjian, MD

MD Anderson Cancer Center, USA

Marcos de Lima

Marcos de Lima, MD

Ohio State University, USA

Michael Osborn

Michael Osborn, MBBS, FRACP, FRCPA

SA Pathology, Adelaide, Australia

Jae Park

Jae Park, MD

Memorial Sloan Kettering Cancer Center, USA

Elizabeth Raetz

Elizabeth Raetz, MD

New York University Grossman School of Medicine, USA

Agenda

This 2-day interactive virtual meeting with global experts will focus on the management of patients with acute leukemia in various countries within the Asia-Pacific region.

DAY 1: Follow presentations, join a debate on sequencing CD19-targeted strategies (systemic therapies vs CAR T), and engage with the faculty in panel discussions on optimal treatment, patient access, and regional challenges across the Asia-Pacific region.

DAY 2: Join the pediatric or adult breakout session to learn about the treatment strategies for newly diagnosed and relapsed/refractory leukemia patients and attend the patient case-based panel discussions focusing on toxicity management.

Day 1 – PLENARY SESSIONS Monday, December 5, 2022

9.00 AM – 12.30 PM (GMT +8) Shanghai
10.00 AM – 1.30 PM (GMT +9) Tokyo
12.00 PM – 3.30 PM (GMT +11) Sydney

Time (GMT +8) Topic Presenter
9.00 AM
9.10 AM
Welcome and Meeting Overview Elias Jabbour, MD
9.10 AM
9.30 AM

What’s New in ALL? Recent Developments in Research and Management

  • Overview of recent data in ALL
Hagop Kantarjian, MD
9.30 AM
9.50 AM

The Clinical Value of MRD in ALL: How MRD Can Guide the Use of Targeted Agents or Immunotherapy

  • Prognostic value, clinical relevance, and MRD-guided treatment strategies
Jae Park, MD
9.50 AM
10.10 AM
Recent Insights in Genetic Variants in ALL: Ph+ and Ph-Like Elias Jabbour, MD
10.10 AM
10.30 AM
Current and Future Role of Transplantation in ALL Marcos de Lima, MD
10.30 AM
11.00 AM

Debate: How to Optimally Sequence CD19-Targeted Approaches in ALL

  • Monoclonal antibodies and bispecifics first
  • CAR T first
  • Discussion and voting
Moderator: Elias Jabbour, MD
Shaun Fleming, MBBS(Hons), FRACP, FRCPA, and Jae Park, MD
All faculty
11.00 AM
11.10 AM
Break  
11.10 AM
11.30 AM

Changing Landscape of Treatment Options in Pediatric and AYA ALL

  • Definition and evolving insights into the treatment of this diverse patient population
Smita Bhatia, MD, MPH (TBC)
11.30 AM
11.55 AM
AYA Patient Case Discussion and Debate: The Evolving Concept of Transplantation in AYA Michael Osborn, MBBS, FRACP, FRCPA, and
Marcos de Lima, MD
11.55 AM
12.20 PM

Interactive Discussion: Regional Challenges of ALL Management

  • Interactive discussion and Q&A (with questions to trigger discussion)
Moderators: Shaun Fleming, MBBS(Hons), FRACP, FRCPA, and Michael Osborn, MBBS, FRACP, FRCPA
All faculty
12.20 PM
12.30 PM
Session Close Elias Jabbour

Day 2 – Virtual Breakout – Adult ALL Sessions Tuesday, December 6, 2022

9.00 AM – 11.45 AM (GMT +8) Shanghai
10.00 AM – 12.45 PM (GMT +9) Tokyo
12.00 PM – 2.45 PM (GMT +11) Sydney

Time (GMT +8) Topic Presenter
9.00 AM
9.10 AM

Session Open

  • ARS questions
Elias Jabbour, MD
9.10 AM
9.35 AM

Optimizing First-Line Therapy in Adult and Older ALL: Integration of Immunotherapy Into Frontline Regimens

  • Optimal use of treatment choices in frontline ALL
Elias Jabbour, MD
9.35 AM
10.00 AM

Current Treatment Options for Relapsed ALL in Adult and Elderly Patients

  • Optimal use of treatment choices in relapsed/refractory ALL
Jae Park, MD
10.00 AM
10.40 AM

ALL Case-Based Panel Discussion

  • Local case 1: Frontline setting
  • Local case 2: Relapsed/refractory setting
  • Discussion and Q&A
Moderators:
Shaun Fleming, MBBS(Hons), FRACP, FRCPA, and Elias Jabbour, MD
Huai-Hsuan Huang, MD
Michael Ashby, MD
All faculty
10.40 AM
10.50 AM
Break  
10.50 AM
11.10 AM

Beyond the Horizon: New and Future Treatment Approaches for Adult and Older ALL

  • Future perspectives and emerging therapies
Jae Park, MD
11.10 AM
11.35 AM

Interactive Discussion: Treatment Landscape Evolution

  • Interactive discussion and Q&A (2–3 questions to trigger discussion; no presentation slides)
Moderator: Elias Jabbour, MD
All faculty
11.35 AM
11.45 AM
Session Close Elias Jabbour, MD

Day 2 – Virtual Breakout – Pediatric ALL Sessions Tuesday, December 6, 2022

9.00 AM – 11.45 AM (GMT +8) Shanghai
10.00 AM – 12.45 PM (GMT +9) Tokyo
12.00 PM – 2.45 PM (GMT +11) Sydney

Time (GMT +8) Topic Presenter
9.00 AM
9.10 AM

Session Open

  • ARS questions
Smita Bhatia, MD, MPH (TBC)
9.10 AM
9.40 AM

Optimizing First-Line Therapy in Pediatric ALL: How to Balance Cure and Long-term Risks?

  • Optimal treatment choices in frontline pediatric ALL, including HSCT
Smita Bhatia, MD, MPH (TBC)
9.40 AM
10.00 AM

Optimal Management and Treatment Coordination of Long-term Toxicities in Pediatric ALL

  • Long-term follow-up care for pediatric ALL survivors
Stephanie Dixon, MD, MPH
10.00 AM
10.40 AM

ALL Case-Based Panel Discussion

  • Local case 1: Frontline setting (10 min)
  • Local case 2: Management of long-term toxicities (10 min)
  • Discussion and Q&A (20 min)
Moderators: Michael Osborn, MBBS, FRACP, FRCPA, and Smita Bhatia, MD, MPH (TBC)
TBC
Claudia Toro, MD
10.40 AM
10.50 AM
Break  
10.50 AM
11.15 AM

Current Treatment Options for Relapsed ALL in Children

  • Optimal treatment choices in relapsed/refractory ALL, including HSCT
Elizabeth Raetz, MD
11.15 AM
11.35 AM

ALL Case-Based Panel Discussion

  • Local case 3: Relapsed/refractory setting
  • Discussion and Q&A
Moderators: Michael Osborn, MBBS, FRACP, FRCPA, and Smita Bhatia, MD, MPH (TBC)
Miri Tukana, MD (TBC)
All faculty
11.35 AM
11.45 AM
Session Close Smita Bhatia, MD, MPH (TBC)